A Phase 2/3 interventional study of Cardiac Resynchronization Therapy with Defibrillation in Heart Failure, Congestive, Ventricular Fibrillation and Tachycardia, Ventricular, sponsored by Boston Scientific Corporation. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2007-01-25.
Sponsored by Boston Scientific Corporation · Phase 2/3, Interventional, and Treatment
The purpose of this study was to determine if cardiac resynchronization therapy when combined with defibrillation is safe and effective in the treatment of symptomatic heart failure.
Patients enrolled received a device with cardiac resynchronization therapy (CRT) and defibrillation. Patients were randomized to CRT on or off for up to six months and evaluated for mortality, hospitalization, and functional outcomes including exercise capacity, quality of life, symptomatic status, and echocardiographic analysis.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's enrollment of 581 is above the median of 72 across 3,736 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →Boston Scientific Corporation is the lead sponsor of 517 studies on the registry; 38 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 56 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Composite of all-cause mortality, heart failure hospitalization, and ventricular tachyarrhythmia
Peak VO2
NYHA Class
Six minute walk distance
Quality of life
Echocardiographic measures
This study is completed, as verified in Jan 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boston Scientific Corporation